BLOG / 🇮🇳 India / index intelligence · · daily

BSE Pharma Sector Regulatory Filings — November 07, 2026

India BSE PHARMA

By Gunpowder Editorial ·

2 high priority 2 medium priority 4 total filings analysed

Executive Summary

The India BSE PHARMA stream on 2026-11-07 is dominated by two index heavyweights reporting Q2 FY27 results: Divi's Laboratories and Zydus Lifesciences.

Divi's delivered exceptional topline growth of 31.8% YoY (consolidated total income ₹3,770 Cr) and PAT growth of 63.6% YoY to ₹1,127 Cr, but the quality of earnings is mixed as forex gains collapsed to ₹24 Cr from ₹63 Cr and operating cash flow weakened sharply to ₹384 Cr in H1 FY27 from ₹1,645 Cr in H1 FY26 due to a ₹1,585 Cr inventory build. Zydus grew revenue 29% YoY to ₹79.1 Bn with a 24% EBITDA margin, but management guided for only single-digit constant-currency US generics growth in FY27 and disclosed USFDA observations at two sites (1 at SEZ-II Ahmedabad, 5 at Moraiya). Across both companies, international/US businesses are the growth engine but face pricing and regulatory headwinds, while India branded formulations grew a solid 19% YoY at Zydus. The common thread is strong revenue momentum offset by margin/quality-of-earnings concerns, with Divi's working capital build and Zydus's US regulatory overhang being the key near-term swing factors. The fourth filing is a low-materiality procedural update from Divi's regarding its earnings call recording, confirming the event occurred on 2026-11-07.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Corporate governance

Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from October 31, 2026.

Investment Signals (10)

  • Consolidated total income grew 31.8% YoY to ₹3,770 Cr in Q2 FY27 (from ₹2,860 Cr), with PBT up 65.0% to ₹1,505 Cr and PAT up 63.6% to ₹1,127 Cr, demonstrating strong operating leverage

  • H1 FY27 consolidated total income grew 28.2% YoY to ₹6,907 Cr and PAT rose 64.4% to ₹2,029 Cr, indicating sustained double-digit growth trajectory

  • Standalone revenue from operations jumped to ₹3,647 Cr in Q2 FY27 from ₹2,660 Cr YoY, a 37.1% increase, showing robust core business momentum

  • Q2 FY27 consolidated revenue grew 29% YoY to ₹79.1 Bn with EBITDA of ₹18.9 Bn at a healthy 24% margin and net profit of ₹9.3 Bn

  • India branded formulations grew 19% YoY, international formulations grew 33% to ₹10 Bn, North America grew 21% to ₹33.1 Bn, and consumer wellness surged 76% to ₹11.2 Bn, showing broad-based growth

  • Specialty products accounted for 16% of US revenues, up approximately 550 bps sequentially, indicating successful mix shift toward higher-value products

  • 4 ANDAs filed, 12 approvals received, and 5 products launched in Q2 FY27, supporting future US revenue pipeline

  • Despite forex headwinds, standalone forex gain was ₹20 Cr for Q2 FY27 and ₹103 Cr for H1 FY27, showing some cushion from currency movements

  • Consolidated inventories rose to ₹5,540 Cr as at 30.09.2026 from ₹3,954 Cr as at 31.03.2026, a 40.1% increase, which could signal preparation for higher future sales but also ties up capital

  • USFDA inspections at SEZ-II Ahmedabad and Moraiya concluded with one and five observations respectively; Moraiya accounts for less than 30% of US revenue, limiting financial impact

Risk Flags (8)

  • ▼

    Operating cash flow weakened significantly to ₹384 Cr in H1 FY27 versus ₹1,645 Cr in H1 FY26, a 76.7% decline, driven by a large inventory build (₹1,585 Cr increase) and higher receivables

  • Divi's Laboratories↓ [MEDIUM RISK]
    ▼

    Forex gain fell sharply to ₹24 Cr in Q2 FY27 from ₹63 Cr YoY, and H1 forex gain dropped to ₹17 Cr from ₹102 Cr, removing a significant earnings tailwind

  • Divi's Laboratories↓ [MEDIUM RISK]
    ▼

    Consolidated other income fell to ₹94 Cr in Q2 FY27 from ₹145 Cr in Q2 FY26, a 35.2% decline, and standalone other income declined to ₹88 Cr from ₹146 Cr YoY, indicating lower non-operating income

  • Zydus Lifesciences↓ [HIGH RISK]
    ▼

    Management guides for only single-digit constant-currency growth in US generics for FY27, a significant deceleration from historical trends, due to Mirabegron competition

  • Zydus Lifesciences↓ [MEDIUM RISK]
    ▼

    USFDA inspections at SEZ-II Ahmedabad and Moraiya concluded with 1 and 5 observations respectively; while Moraiya is <30% of US revenue, the observations could escalate regulatory risk

  • Zydus Lifesciences↓ [HIGH RISK]
    ▼

    US generics face Mirabegron competition, which may pressure pricing and volumes in a key product, contributing to the weak FY27 guidance

  • Divi's Laboratories↓ [MEDIUM RISK]
    ▼

    Inventory build of ₹1,585 Cr in H1 FY27 (inventories up 40.1% from March 2026) may indicate slowing demand or inefficiencies if not converted to sales, risking future write-downs

  • Sector [MEDIUM RISK]
    ▼

    Both Divi's and Zydus show reliance on international markets (US for Zydus, exports for Divi's) which are exposed to currency volatility and regulatory scrutiny, as evidenced by forex swings and USFDA observations

Opportunities (8)

  • Divi's Laboratories↓ (OPPORTUNITY)
    ◆

    Strong 63.6% YoY PAT growth and 65.0% PBT growth in Q2 FY27 despite forex headwinds demonstrate underlying operational strength; if forex stabilizes, earnings could surprise further

  • Divi's Laboratories↓ (OPPORTUNITY)
    ◆

    Inventory build of ₹1,585 Cr could be a precursor to strong revenue recognition in upcoming quarters if it reflects order backlog or capacity expansion; watch for conversion in Q3 FY27

  • Zydus Lifesciences↓ (OPPORTUNITY)
    ◆

    Consumer wellness segment surged 76% YoY to ₹11.2 Bn, a high-growth area that could command premium valuation and offset slower US generics

  • Zydus Lifesciences↓ (OPPORTUNITY)
    ◆

    Specialty products now 16% of US revenues, up ~550 bps sequentially, indicating successful pivot to higher-margin complex products; continued mix shift could improve US margins

  • Zydus Lifesciences↓ (OPPORTUNITY)
    ◆

    12 ANDA approvals and 5 launches in Q2 FY27 provide a pipeline for US growth despite near-term Mirabegron competition; new products could offset generic price erosion

  • Zydus Lifesciences↓ (OPPORTUNITY)
    ◆

    India branded formulations grew 19% YoY, outperforming the broader Indian pharma market, suggesting market share gains and strong brand equity

  • Divi's Laboratories↓ (OPPORTUNITY)
    ◆

    Despite weak H1 cash flow, the company remains profitable with strong margins; if working capital normalizes in H2, cash flow could rebound sharply

  • Sector (OPPORTUNITY)
    ◆

    Both companies are investing in growth (Divi's inventory, Zydus R&D/launches), which could lead to operating leverage and margin expansion once investments mature

Sector Themes (5)

  • Strong Topline Growth with Margin Pressure (THEME)
    ◆

    Both Divi's (31.8% YoY revenue growth) and Zydus (29% YoY revenue growth) reported robust double-digit topline expansion, but earnings quality is mixed due to forex headwinds (Divi's) and US pricing pressure (Zydus), suggesting sector-wide revenue momentum but varying margin outcomes

  • US Regulatory Overhang (THEME)
    ◆

    Zydus disclosed USFDA observations at two sites (1 and 5 observations), highlighting persistent regulatory scrutiny for Indian pharma companies in the US market; Divi's also has significant US exposure, though no specific USFDA update in these filings

  • Working Capital Build (THEME)
    ◆

    Divi's reported a ₹1,585 Cr inventory increase in H1 FY27, contributing to a sharp operating cash flow decline; this could be a sector-wide phenomenon as companies build inventory for anticipated demand or to mitigate supply chain risks

  • Mix Shift to Specialty/Consumer (THEME)
    ◆

    Zydus's specialty products (16% of US revenues, up 550 bps) and consumer wellness (+76% YoY) growth indicate a sector trend toward higher-margin, less price-sensitive segments to counter generic erosion

  • Forex Volatility Impact (THEME)
    ◆

    Divi's forex gain dropped from ₹63 Cr to ₹24 Cr YoY, and other income fell, showing how currency fluctuations can significantly impact earnings for export-oriented Indian pharma companies

Watch List (6)

  • 👁

    Monitor Q3 FY27 results for conversion of ₹1,585 Cr inventory build into sales and any normalization in operating cash flow; earnings call recording from 2026-11-07 available for further details

  • 👁

    Watch for forex trends and other income recovery in upcoming quarters, as these have been significant swing factors in Q2 FY27

  • 👁

    Watch for resolution of USFDA observations at SEZ-II Ahmedabad and Moraiya; any escalation (e.g., Warning Letter) could impact US revenue

  • 👁

    Monitor US generics performance in Q3 FY27, especially Mirabegron competition and whether single-digit constant-currency growth guidance for FY27 is revised

  • 👁

    Track specialty product share of US revenues and consumer wellness growth for signs of sustainable mix shift

  • Sector (WATCH)
    👁

    Watch for other BSE PHARMA constituents reporting Q2 FY27 results in the coming weeks for confirmation of sector-wide trends in revenue growth, margin pressure, and US regulatory updates

Filing Analyses (4)
Divi's Laboratories Limited Corporate Governance mixed materiality 8/10

07-11-2026

Divi's Laboratories reported consolidated total income of ₹3770 crore for Q2 FY27, up 31.8% YoY from ₹2860 crore, with PBT rising 65.0% to ₹1505 crore and PAT up 63.6% to ₹1127 crore. However, forex gain fell sharply to ₹24 crore from ₹63 crore YoY, and for H1 the forex gain dropped to ₹17 crore from ₹102 crore, while other income also declined to ₹94 crore from ₹145 crore. Operating cash flow weakened significantly to ₹384 crore in H1 FY27 versus ₹1645 crore in H1 FY26, driven by a large inventory build (₹1585 crore increase) and higher receivables.

  • · Consolidated inventories rose to ₹5540 Cr as at 30.09.2026 from ₹3954 Cr as at 31.03.2026, driving a ₹1585 Cr inventory build in H1 FY27 cash flow
  • · Consolidated other income fell to ₹94 Cr in Q2 FY27 from ₹145 Cr in Q2 FY26
  • · Standalone forex gain was ₹20 Cr for Q2 FY27 and ₹103 Cr for H1 FY27
  • · Consolidated EPS (basic) was ₹42.49 for Q2 FY27 vs ₹25.97 in Q2 FY26; H1 FY27 EPS ₹76.44 vs ₹46.46
  • · Dividend paid to shareholders was ₹797 Cr in H1 FY27, similar to ₹796 Cr in H1 FY26
  • · Consolidated trade receivables increased to ₹3487 Cr from ₹2984 Cr as at 31.03.2026
  • · Year ended 31.03.2026 included an exceptional item of ₹74 Cr for impact of new labour codes
  • · Statutory auditors Price Waterhouse issued an unmodified limited review report on both standalone and consolidated statements
  • · Board approved the results at its meeting held on November 07, 2026
Divi's Laboratories Limited Market Update positive materiality 8/10

07-11-2026

Divi's Laboratories reported consolidated total income of ₹3770 crore for Q2 FY27, up 31.8% YoY from ₹2860 crore, with consolidated PAT rising 63.6% YoY to ₹1127 crore from ₹689 crore. For H1 FY27, consolidated total income grew 28.2% YoY to ₹6907 crore and PAT rose 64.4% to ₹2029 crore. However, forex gains fell sharply to ₹24 crore in the quarter versus ₹63 crore a year earlier (and ₹17 crore vs ₹102 crore for the half year), while standalone other income declined to ₹88 crore from ₹146 crore YoY, tempering the otherwise strong operational performance.

  • · Standalone other income declined to ₹88 crore in Q2 FY27 from ₹146 crore in Q2 FY26
  • · Standalone revenue from operations rose to ₹3647 crore in Q2 FY27 from ₹2660 crore YoY
  • · Consolidated inventories increased to ₹5540 crore as at 30.09.2026 from ₹3954 crore as at 31.03.2026
  • · Net cash inflow from operating activities (consolidated) fell to ₹384 crore for H1 FY27 from ₹1645 crore in H1 FY26
  • · Dividend paid to shareholders was ₹797 crore in H1 FY27
  • · Company operates as a single reportable business segment per Ind AS 108
  • · Statutory auditors issued an unmodified limited review report
  • · Board meeting approving results held on November 07, 2026
Zydus Lifesciences Limited Analyst/Investor Meet mixed materiality 8/10

07-11-2026

Zydus Lifesciences reported Q2 FY27 consolidated revenue of ₹79.1 billion, up 29% YoY, with EBITDA of ₹18.9 billion at a 24% margin and net profit of ₹9.3 billion. Growth was broad-based: India branded formulations +19% YoY, international formulations +33% to ₹10 billion, North America +21% to ₹33.1 billion, and consumer wellness +76% to ₹11.2 billion. However, US generics face Mirabegron competition and management guides for only single-digit constant-currency growth in FY27, while USFDA inspections at SEZ-II Ahmedabad and Moraiya concluded with one and five observations respectively.

  • · USFDA inspections at SEZ-II Ahmedabad and Moraiya concluded with one and five observations respectively; Moraiya accounts for less than 30% of US revenue.
  • · US generics: 4 ANDAs filed, 12 approvals received, 5 products launched in Q2 FY27.
  • · Specialty products accounted for 16% of US revenues, up approximately 550 basis points sequentially.
  • · Saroglitazar US launch targeted for March 2027; annual commercial expense expected at around $100 million.
  • · Management guides for single-digit constant-currency growth in US business for FY27, with Mirabegron competition already factored in.
  • · Net debt reduced to ₹5200 crore from ₹5900 crore in the prior quarter.
  • · R&D spend at approximately ₹650 crore per quarter, guided at 8-8.5% of revenue.
  • · Other expenses excluding R&D and Saro commercialization expected at ₹2000 to 2050 crore.
  • · Vaccine business annualized run rate at ₹450 crore, expected to double in 3-4 years.
  • · India biosimilar business has crossed ₹1000 crore in revenue.
  • · Planned 15-20 launches (ANDAs, 505(b)(2)s, FTFs) over the next two to three quarters.
  • · Transdermal patch capacity could double in at least a year; current demand exceeds supply by 50%.
Divi's Laboratories Limited Analyst/Investor Meet neutral materiality 2/10

07-11-2026

Divi's Laboratories Limited disclosed via a Regulation 30 filing to NSE and BSE that the audio recording of its Q2 FY27 earnings conference call, held on November 07, 2026 at 14:00 hrs IST, has been uploaded to the Investors Relations section of its website. The call covered the quarter and half year ended September 30, 2026. The filing itself contains no financial figures or performance data, only the availability of the recording.

  • · Trading Symbol: DIVISLAB; BSE Scrip Code: 532488
  • · Earnings call held on November 07, 2026 at 14:00 hrs IST
  • · Recording uploaded at divislabs.com/wp-content/uploads/2026/11/Q2FY27-earnings-call-07.11.2026.webm
  • · Filing made under Regulation 30 of SEBI (LODR) Regulations, 2015, further to intimation dated November 02, 2026
  • · Filing digitally signed by M. Satish Choudhury on 2026.11.07 at 17:01:17 +05:30

Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 4 filings

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: BSE Pharma Sector Regulatory Filings

🇮🇳 More from India

View all →